BioCardia
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
320 Soquel Way, Sunnyvale, California, 9...Phone Number
(650) 226-0120Website
www.biocardia.comRevenue
-Stock Symbol
BCDAIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
1
1
1
About BioCardia
BioCardia is a clinical-stage regenerative medicine company focused on developing novel therapeutics for cardiovascular diseases with significant unmet medical needs. The company is advancing proprietary, comprehensive biotherapeutic solutions through its CardiAMP and CardiALLO therapy programs. Clinical results supporting both programs are compelling and build upon some of the most rigorous data to date in the field, utilizing intramyocardial delivery of marrow-derived cells.Explore more
BioCardia Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BioCardia your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if BioCardia had a recent Job posting/layoffs
Earning: See what the market has to say on BioCardia recently announced quarterly report
BioCardia, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if BioCardia is spiking on competitors!
Product Launch: Get notified when BioCardia launches new products
Funding: Get notified immidiatlly once BioCardia has new funding data
Check if BioCardia has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at BioCardia
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at BioCardia
Find 2 more new buyers
Compare Similar Companies to BioCardia
Compare insights from companies similar to BioCardia, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
BioCardia is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
BioCardia is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about BioCardia.
BioCardia financials insights
Gather financial insights about BioCardia, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Debt
$4.4M
2026
Stock/Share Issuance
$4.4M
BioCardia Tech Stack
A closer look at the technologies used by BioCardia
Most Recent Scoops
Earnings
BioCardia has reported net cash used in operations of approximately $1.7 million for the three months ended June 2026, a slight increase from $1.6 million for the same period in 2025, and $3.4 million for the six months ended June 2026, compared to $3.3 million for the six months ended June 2025, with the increases primarily attributed to the timing of supplier payments.
Earnings, Finance, Financial Operations
Project
BioCardia has announced that the FDA identified two pathways for marketing clearance of its Helix Transendocardial Delivery Catheter System, with the agency's preferred route being simultaneous approval alongside the CardiAMP Cell Therapy System, and also suggested a follow-on pre-submission could enable approval via the de novo pathway.
Product Launch, Medical Research
Earnings
BioCardia has reported total expenses of $1.6 million for Q2 2026, a decrease of $0.4 million compared to $2.1 million in Q2 2025, and $3.9 million for the six months ended June 2026, a decrease of $0.9 million from $4.8 million for the same period in 2025.
Earnings, Accounting, Financial Reporting, Finance
Project
BioCardia has received guidance from Japan's PMDA requesting additional clinical data for its CardiAMP cell therapy submission, including confirmation of guideline-directed medical therapy for enrolled patients, details on all-cause death and device implantation events, and an initial proposal for the post-marketing study covering center selection, physician training, and outcomes assessment.
Clinical Operations
Project
Clinical Operations
BioCardia News & Media
BioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for Approval
SUNNYVALE, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces receipt of FDA confirmation of the outcome of its Pre-Submission Meeting on the Helix Transendocardial Delivery Catheter System (Helix).BioCardia Inc (BCDA) (Q2 2026) Earnings Call Highlights: Regulatory Wins in Japan and US ...
BioCardia advances toward Japanese Shonin submission and FDA approval pathways while managing cash runway into 2027.BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results
SUNNYVALE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the second quarter 2026 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2026 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in whichBioCardia to Host Q2 2026 Financial Results and Corporate Update Conference Call on August 12, 2026
SUNNYVALE, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the second quarter of 2026 by conference call on Wednesday, August 12, 2026 at 4:30 PM EDT. Following management’s formal remarks, there will be a question-and-answer session.
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BioCardia
Sign Up For FreeTo access detailed company insights
BioCardia is a clinical-stage regenerative medicine company focused on developing novel therapeutics for cardiovascular diseases with significant unmet medical needs. The company is advancing proprietary, comprehensive biotherapeutic solutions through its CardiAMP and CardiALLO therapy programs. Clinical results supporting both programs are compell... Read More
